Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 1b/2 study of crizotinib alone or with temsirolimus in ALK-, ROS1-, or MET-positive malignancies
NL-OMON60919Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib and temsirolimus in neuroblastoma, rhabdomyosarcoma (RMS), inflammatory pseudotumor (IPT) and 3 more (3 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities and Overall response rate. Started Apr 2018; status: recruiting.
02
Drugs
crizotinibtemsirolimus
03
Conditions
neuroblastomarhabdomyosarcoma (RMS)inflammatory pseudotumor (IPT)anaplastic large cell lymphoma (ALCL)Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on NL-OMON60919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60919.